Illicit drug use by pregnant women infected with HIV

被引:0
|
作者
Melo, Victor Hugo [2 ]
Machahado Botelho, Ana Paula [3 ]
Martins Maia, Marcelle Marie [4 ]
Correa Junior, Mario Dias [1 ]
Pinto, Jorge Andrade [5 ]
机构
[1] Univ Fed Minas Gerais, Fac Med, Dept Ginecol & Obstet, Ave Alfredo Balena 190, BR-30130100 Belo Horizonte, MG, Brazil
[2] Univ Fed Minas Gerais, Fac Med, Programa Posgrad Saude Mulher, Belo Horizonte, MG, Brazil
[3] Univ Fed Minas Gerais, Curso Grad Med, Belo Horizonte, MG, Brazil
[4] Univ Fed Minas Gerais, Grp Pesquisa HIV Materno Infantil, Belo Horizonte, MG, Brazil
[5] Univ Fed Minas Gerais, Fac Med, Dept Pediat, Belo Horizonte, MG, Brazil
来源
关键词
Drug users; Crack cocaine; Pregnancy complications; infectious; HIV infections; Infectious disease transmission; vertical;
D O I
10.1590/SO100-720320140005155
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
PURPOSE: To determine if illicit drug use increases the vertical transmission of HIV, to identify the risk factors involved in mother and child health and the prevalence of illicit drug use among these pregnant women. METHODS: Sixty-four (7.6%) of 845 pregnant women from the metropolitan region of Belo Horizonte, Minas Gerais, Brazil, attended in the service between October 1997 and February 2012 reported the use of illicit drugs. Cases were HIV- positive drug users (n=64) and controls were women who did not use drugs (n=192). Three controls were selected for each case. Several conditions of exposure were considered in the control group such as tobacco use, alcohol use, alcohol and tobacco use, maternal age, educational level, ethnicity, and marital status. Problems during the prenatal period, delivery and postpartum, vertical HIV transmission and neonatal outcomes were also investigated. RESULTS: Univariate analysis showed as significant variables: maternal age, tobacco use, number of prenatal care visits, antiretroviral therapy, mode of infection, and viral load at delivery. Logistic regression revealed as significant variables: maternal age (less than 25 years); tobacco use, and number of prenatal care visits (less than 6). The vertical transmission of HIV was 4,8% (95% CI 1.7-13.3) among drug users and 2,1% (95% CI 0.8-5.2) in the control group, with no statistically significant difference between groups. Neonatal complications were more frequent among drug users, but also with no statistically significant difference between groups. CONCLUSION: The use of illicit drug is frequent during pregnancy among HIV- infected women. The approach to illicit drug use should be routine during prenatal care visits. These women are more discriminated against and tend to deny their habits or do not seek prenatal care. There was no difference in vertical virus transmission between groups, probably indicating adherence to antiretroviral use for antiretroviral therapies during pregnancy.
引用
收藏
页码:555 / 561
页数:7
相关论文
共 50 条
  • [41] Neopterin in HIV-infected pregnant women.
    Watchi, R
    Morrison, J
    Stek, A
    PEDIATRIC RESEARCH, 1996, 39 (04) : 1110 - 1110
  • [42] Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
    Mulligan, Nikki
    Schalkwijk, Stein
    Best, Brookie M.
    Colbers, Angela
    Wang, Jiajia
    Capparelli, Edmund V.
    Molto, Jose
    Stek, Alice M.
    Taylor, Graham
    Smith, Elizabeth
    Tenorio, Carmen Hidalgo
    Chakhtoura, Nahida
    van Kasteren, Marjo
    Fletcher, Courtney V.
    Mirochnick, Mark
    Burger, David
    FRONTIERS IN PHARMACOLOGY, 2016, 7
  • [43] Characteristics of HIV-infected pregnant women in the Bahamas
    Gomez, MP
    Bain, RM
    Major, C
    Gray, H
    Read, SE
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 12 (04): : 400 - 405
  • [44] Preventing Malaria in HIV-Infected Pregnant Women
    Bulterys, Philip L.
    Kaplan, Jonathan E.
    Gutman, Julie
    CLINICAL INFECTIOUS DISEASES, 2014, 58 (05) : 660 - 662
  • [45] Antiretroviral therapy for pregnant HIV-infected women
    Luber, AD
    Dong, BJ
    ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) : 509 - 509
  • [46] Trends in zidovudine prescription for pregnant women infected with HIV
    Lansky, A
    Jones, JL
    Wan, PCT
    Lindegren, ML
    Wortley, P
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 18 (03): : 289 - 292
  • [47] Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women
    Tran, Anna H.
    Best, Brookie M.
    Stek, Alice
    Wang, Jiajia
    Capparelli, Edmund V.
    Burchett, Sandra K.
    Kreitchmann, Regis
    Rungruengthanakit, Kittipong
    George, Kathleen
    Cressey, Tim R.
    Chakhtoura, Nahida
    Smith, Elizabeth
    Shapiro, David E.
    Mirochnick, Mark
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (03) : 289 - 296
  • [48] Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir
    Caswell, R. J.
    Phillips, D.
    Chaponda, M.
    Khoo, S. H.
    Taylor, G. P.
    Ghanem, M.
    Poulton, M.
    Welch, J.
    Gibbons, S.
    Jackson, V.
    Lambert, J. S.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2011, 22 (01) : 11 - 14
  • [49] HIV AND PREGNANCY - AN ANTENATAL PROGRAM FOR HIV INFECTED PREGNANT-WOMEN
    LINDGREN, S
    OTTENBLAD, C
    BENGTSSON, AB
    NEMETH, A
    BOHLIN, AB
    FREE WOMAN: WOMENS HEALTH IN THE 1990S, 1989, : 750 - 757
  • [50] Pregnant Women Care for Drug Use
    Huber, Georgine
    Seelbach-Goebel, Birgit
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2015, 75 (05) : 419 - 423